Patents by Inventor Anan Chuntharapai

Anan Chuntharapai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DR4 antibodies and uses thereof
    Publication number: 20040120947
    Abstract: Death Receptor 4 (DR4) antibodies are provided. The DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.
    Type: Application
    Filed: September 11, 2003
    Publication date: June 24, 2004
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Anan Chuntharapai, Kelly Dodge, Kyung Jin Kim
  • Monoclonal antibodies to type I interferon receptor
    Patent number: 6713609
    Abstract: Anti-IFNAR1 monoclonal antibodies with neutralizing activities against the anti-viral cytopathic effects of various type I interferons are provided.
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: March 30, 2004
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Kyung Jin Kim, Richard B. Love, Ji Lu
  • Apo-2 receptor
    Publication number: 20040009552
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: April 25, 2003
    Publication date: January 15, 2004
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Anti-interferon-alpha antibodies
    Publication number: 20030166228
    Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-&agr; monoclonal antibodies with broad reactivity against various IFN-&agr; subtypes. The invention further relates to the use of such anti-IFN-&agr; antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-&agr;, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
    Type: Application
    Filed: January 9, 2002
    Publication date: September 4, 2003
    Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
  • Apo-2 receptor
    Publication number: 20030148455
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: November 6, 2002
    Publication date: August 7, 2003
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Apo-2DcR
    Publication number: 20030138915
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: September 11, 2002
    Publication date: July 24, 2003
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, Anan Chuntharapai, Austin Gurney, Kyung Jin Kim, William I. Wood
  • Monoclonal antibodies to IFNAR2
    Publication number: 20030018174
    Abstract: Anti-INFAR2 monoclonal antibodies with blocking antibodies against the INFAR2 binding of various type I interferons are provided.
    Type: Application
    Filed: January 17, 2002
    Publication date: January 23, 2003
    Applicant: Genentech, Inc.
    Inventors: Kyung Jin Kim, Anan Chuntharapai, Ji Lu
  • Apo-2 receptor
    Publication number: 20030017161
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: July 29, 2002
    Publication date: January 23, 2003
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Apo-2 receptor
    Publication number: 20020150985
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: November 2, 2001
    Publication date: October 17, 2002
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Apo-2DcR
    Publication number: 20020102706
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: June 21, 2001
    Publication date: August 1, 2002
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, Anan Chuntharapai, Austin Gurney, Kyung Jin Kim, William I. Wood
  • Antibodies to &agr;v&bgr;3 integrin
    Patent number: 6369204
    Abstract: The invention relates to monoclonal antibodies to the &agr;v&bgr;3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on &agr;v&bgr;3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: April 9, 2002
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Antibodies to &agr;v&bgr;3 integrin
    Patent number: 6359126
    Abstract: The invention relates to monoclonal antibodies to the &agr;v&bgr;3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies recognize unique epitopes on &agr;v&bgr;3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: March 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
    Publication number: 20020004227
    Abstract: A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind.
    Type: Application
    Filed: April 9, 2001
    Publication date: January 10, 2002
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, K. Jin Kim
  • Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
    Patent number: 6252050
    Abstract: A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: June 26, 2001
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, K. Jin Kim
  • Apo-2 ligand
    Patent number: 6046048
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Grant
    Filed: January 8, 1997
    Date of Patent: April 4, 2000
    Assignee: Genetech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Antibodies to PF4A receptor
    Patent number: 5874543
    Abstract: cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: February 23, 1999
    Assignee: Genetech, Inc.
    Inventors: Anan Chuntharapai, James Lee, Caroline Hebert, K. Jin Kim
  • Antibodies to a human PF4 superfamily receptor
    Patent number: 5840856
    Abstract: cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: November 24, 1998
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, James Lee, Caroline Hebert, K. Jin Kim
  • Antibodies to .alpha.v.beta.3 integrin
    Patent number: 5652109
    Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: July 29, 1997
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Antibodies to .alpha.v.beta.3 integrin
    Patent number: 5652110
    Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: July 29, 1997
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Antibody to osteoclast alphavbeta3 ntegrin
    Patent number: 5578704
    Abstract: Hybridoma cell line, ATCC HB 11029, which produces murine monoclonal antibody, 10C4.1.3 which specifically binds to alphavbeta3 integrin on human osteoclasts, and is capable of blocking binding of alphavbeta3 integrin to fibrinogen or to vitronectin. The antibody is useful for detecting alphavbeta3 integrin on cells in histological and diagnostic assays, and to treat disease conditions that are characterized by excessive bone resorption.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: November 26, 1996
    Assignee: Genentech, Inc.
    Inventors: Kyung J. Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai